What I am working with: a residual-solvent screen · cagrilintide.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
What is the actual trade-off, and does it matter at the scale I am working at?
The honest answer is that you cannot know for certain what you have without a content assay, and the purity number alone is not enough.
For peptides at 214 nanometres the response is roughly proportional to the number of peptide bonds, so truncation impurities have lower response factors and overestimate content.
Specifically, water content and counter-ion content are part of the gross mass but not part of the content assay result, which is why the two do not sum to label claim.
Where content data have been published from testing services on common peptides, the spread between services on identical material is typically a few per cent.
One qualification: a single result from a single vial is a point estimate, and repeating the assay on a second aliquot is worth doing if the first result is surprising.
If a supplier gives you content without the standard's purity, ask them to provide it.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe underlying point is that content assay requires a reference standard of known purity and traceability, which is why it costs more than purity testing does.
System suitability for a quantitative method is stricter than for purity because a small systematic error in the standard directly translates into an error in the sample result.
In practice, running multiple independent aliquots of the same sample should give results that agree to within the method precision, which is usually one to three per cent.
Pharmacopoeial guidance on quantitative methods specifies validation steps for linearity, range, accuracy and precision that most research-grade work does not claim to meet.
The practical summary: if you are ordering from a new supplier, budget for content assay on the first lot.
The part that matters: quantified content is how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard, and it is the only measurement that directly answers that question.
If a sample shows high purity but low content, the explanation is usually that the standard used for quantitation had a different purity than claimed.
Quantitation against a certified reference material assumes the sample and standard are treated identically through the analytical method, which is why the method for calibration matters as much as the method for measurement.
The relative standard deviation on replicate quantitations of a homogeneous sample should be below two per cent when the method is under control.
Ask for both the purity and the content, and do not accept purity alone.
edited 12 Dec 2025 by fill_volume — tightened the wording; no substantive change
Put another way, the label claim is usually the gross mass of the lyophilised solid, which is not the same as the content, because the solid contains water, counter-ion and other non-peptide mass.
If the standard and sample have different absorption coefficients at the detection wavelength, the response factors differ and the inference fails.
The limitation is that a quantitative method is only as good as the standard it uses, and a cheap standard is a false economy.
If a supplier gives you content without the standard's purity, ask them to provide it.
Most research-grade certificates report purity without content, which is exactly backwards from what users actually need.
Peak area for a standard of known weight produces a response factor — area per unit mass — which is then applied to the sample peak to infer sample mass.
Quantitation against a standard requires that the standard be traceable to a national metrology institute, and certificates for research-grade standards claim that traceability.
The caveat is that content assay costs more than purity, so most people do not do it, which is exactly why it is valuable on the first lot from a new supplier.
The practical summary: if you are ordering from a new supplier, budget for content assay on the first lot.
edited 10 Feb 2026 by Dr_Ingrid_Baumgartner — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.